Osteogenesis Imperfecta Types I, III, and IV: Effect of Pamidronate Therapy on Bone and Mineral Metabolism
- 1 March 2003
- journal article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 88 (3) , 986-992
- https://doi.org/10.1210/jc.2002-021371
Abstract
Cyclical iv therapy with pamidronate improves the clinical course in children and adolescents with osteogenesis imperfecta (OI). In this study we evaluated the effect of this therapy on bone and mineral metabolism in 165 patients with OI types I, III, and IV (age, 2 wk to 17.9 yr; 86 girls and 79 boys). All patients received iv pamidronate infusions on 3 successive days, administered at age-dependent intervals of 2–4 months. During the 3 d of the first infusion cycle, serum concentrations of ionized calcium dropped by 0.14 ± 0.008 mmol (mean ± se; P < 0.001), and serum PTH levels transiently almost doubled (P < 0.001). At the same time, urinary excretion of the bone resorption marker type I collagen N-telopeptide related to creatinine (uNTX/uCr) decreased by 61–73% (P < 0.001). Two to 4 months later, ionized calcium had returned to pretreatment levels, and uNTX/uCr remained 30–35% lower than at baseline (P < 0.001). During 4 yr of pamidronate therapy (n = 40 patients), ionized calcium levels remained stable, but PTH levels increased by about 30% (P < 0.01). uNTX/uCr, expressed as a percentage of the age- and sex-specific mean value in healthy children, decreased from 132 ± 13% (mean ± se) at baseline to 49 ± 3% after 4 yr of therapy (P < 0.001). In conclusion, serum calcium levels can decrease considerably during and after pamidronate infusions, requiring close monitoring especially at the first infusion cycle. In long-term therapy, bone turnover is suppressed to levels lower than those in healthy children. The consequences of chronically low bone turnover in children with OI are unknown at present.Keywords
This publication has 21 references indexed in Scilit:
- Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone diseaseBone, 2002
- Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfectaArchives of Disease in Childhood, 2002
- Osteogenesis Imperfecta Type VI: A Form of Brittle Bone Disease with a Mineralization DefectJournal of Bone and Mineral Research, 2002
- Type V Osteogenesis Imperfecta: A New Form of Brittle Bone DiseaseJournal of Bone and Mineral Research, 2000
- Static and dynamic bone histomorphometry in children with osteogenesis imperfectaBone, 2000
- Cyclic Administration of Pamidronate in Children with Severe Osteogenesis ImperfectaNew England Journal of Medicine, 1998
- Hypercalciuria in osteogenesis imperfecta: A follow-up study to assess renal effectsBone, 1995
- Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfectaJournal of Bone and Mineral Research, 1994
- Hypercalciuria in children severely affected with osteogenesis imperfectaThe Journal of Pediatrics, 1991
- Genetic heterogeneity in osteogenesis imperfecta.Journal of Medical Genetics, 1979